

Joint Meeting of the  
CDER Psychopharmacologic Drugs Advisory Committee &  
FDA Pediatric Advisory Committee  
September 13-14, 2004

**CONSULTANTS AND GUESTS**

*Special Government Employee (SGE) Consultants (voting)*

Norman Fost, M.D., M.P.H.  
Professor of Pediatrics and Bioethics  
University of Wisconsin Medical School  
600 Highland Avenue  
Madison, Wisconsin 53792

Steven Ebert, Pharm. D. (Consumer Representative)  
Department of Pharmacy  
Meriter Hospital  
202 South Park Street  
Madison, Wisconsin 53715

Charles E. Irwin, Jr., M.D.  
Pediatrics/ Adolescent Medicine  
University of California, San Francisco: Laurel  
3333 California Street, Suite 245  
San Francisco, California 94143-0503

James M. Perrin, M.D.  
Center for Child and Adolescent Health Policy  
50 Staniford Street, Suite 901  
Massachusetts General Hospital for Children  
Boston, Massachusetts 02114

Laurel K. Leslie, M.D., F.A.A.P.  
Pediatrician/Research Scientist  
Child & Adolescent Services Research Center  
C/o Children's Hospital  
3020 Children's Way, MC5033  
San Diego, California 92123

Cynthia R. Pfeffer, M.D.  
Professor of Psychiatry  
Weill Medical of Cornell University  
New York Presbyterian Hospital  
21 Blooming Dale Road  
White Plains, New York 10605

*SGE Patient Representative (voting)*

Gail W. Griffith, Washington, D.C.

*Guest Speakers (non-voting)*

Kelly Posner, Ph.D.  
Department of Child Psychiatry  
New York State Psychiatric Institute  
1051 Riverside Drive  
New York, New York 10032

John March, M.D., M.P.H.  
Department of Psychiatry & Behavioral Sciences  
Duke Child & Family Study Center  
718 Rutherford Street, Room 132  
Durham, North Carolina 27710

*Guests (non-voting)*

Samuel Maldonado, M.D., M.P.H.  
(Industry Representative)  
920 Route 202 South  
Raritan, New Jersey 08869

Barbara Stanley, Ph.D.  
Department of Child Psychiatry  
New York State Psychiatric Institute  
1051 Riverside Drive  
New York, New York 10032

Madelyn Gould, Ph.D., M.P.H.  
Department of Child Psychiatry  
New York State Psychiatric Institute  
1051 Riverside Drive  
New York, New York 10032

---

*FDA Participants at the Table (non-voting)*

Robert Temple, M.D.  
Director, Office of Drug Evaluation I, CDER

M. Dianne Murphy, M.D.  
Director, Office of Pediatric Therapeutics,  
Office of the Commissioner

Russell G. Katz, M.D.  
Director  
Division of Neuropharmacological Drug Products, CDER

Anne Trontell, M.D., M.P.H.  
Deputy Director, Office of Drug Safety, CDER

Thomas Laughren, M.D.  
Team Leader  
Division of Neuropharmacological Drug Products, CDER